Pharmaceutical Technology on MSN
Harmony’s cannabidiol drug flops in pivotal Fragile X Syndrome trial
Share price in Harmony tumbled in the wake of the Phase III trial miss, with a route to market for ZYN002 looking bleak.
2monon MSN
Experts call for greater physician awareness and screening of fragile X-related conditions
UC Davis MIND Institute researchers Randi and Paul Hagerman are calling for increased awareness and screening for fragile X-associated conditions. In a new paper published in the New England Journal ...
Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced topline results from its Phase 3 registrational clinical ...
Research on fragile X syndrome, the most common inherited cause of mental retardation, has focused mostly on how the genetic defect alters the functioning of neurons in the brain. A new study focusing ...
Law enforcement determined that both victims had Fragile X Syndrome, a genetic disorder that is the most common cause of ...
Studies of mouse models of Fragile X syndrome and Phelan-McDermid syndrome show that treatment with cannabidiol (CBD) and the diabetes drug metformin can alleviate behavioral difficulties, according ...
Servier acquires KER-0193, a potential treatment for Fragile X syndrome, developed by Kaerus Bioscience, a Medicxi company KER-0193, a novel, orally bioavailable small molecule, was granted Orphan ...
Harmony Biosciences Holdings faces setbacks after a failed trial and sNDA rejection. Click here to find out why HRMY is a Hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback